Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased frequency of CD4+ cells expressing CD161 in cancer patients.
Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. Iliopoulou EG, et al. Among authors: ardavanis a. Clin Cancer Res. 2006 Dec 1;12(23):6901-9. doi: 10.1158/1078-0432.CCR-06-0977. Clin Cancer Res. 2006. PMID: 17145807
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.
Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. Iliopoulou EG, et al. Among authors: ardavanis a. Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. doi: 10.1007/s00262-010-0904-3. Epub 2010 Aug 12. Cancer Immunol Immunother. 2010. PMID: 20703455 Free PMC article. Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: ardavanis a. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: ardavanis a. Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751. Oncotarget. 2016. PMID: 27589688 Free PMC article. Clinical Trial.
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN. Fortis SP, et al. Among authors: ardavanis a. J Immunother Cancer. 2017 Apr 18;5:39. doi: 10.1186/s40425-017-0240-7. eCollection 2017. J Immunother Cancer. 2017. PMID: 28428887 Free PMC article.
Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN. Fortis SP, et al. Among authors: ardavanis a. J Immunother Cancer. 2017 May 30;5:48. doi: 10.1186/s40425-017-0248-z. eCollection 2017. J Immunother Cancer. 2017. PMID: 28572978 Free PMC article.
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, Vlachodimitropoulos D, Perez SA, Baxevanis CN. Sofopoulos M, et al. Among authors: ardavanis a. Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745. doi: 10.1007/s00262-019-02407-8. Epub 2019 Oct 9. Cancer Immunol Immunother. 2019. PMID: 31598757 Free PMC article.
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Brown TA 2nd, et al. Among authors: ardavanis a. Breast Cancer Res Treat. 2020 Jun;181(2):391-401. doi: 10.1007/s10549-020-05638-x. Epub 2020 Apr 22. Breast Cancer Res Treat. 2020. PMID: 32323103 Free PMC article. Clinical Trial.
124 results